证券代码：002942 证券简称：新农股份 公告编号：2024-028 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1.本次股东大会未出现否决提案的情形。 2.本次股东大会未涉及变更以往股东大会已通过的决议。 浙江新农化工股份有限公司 2023 年年度股东大会决议公告 一、会议召开和出席情况 （一）会议召开情况 1.召开时间 现场会议时间：2024 年 5 月 22 日（星期三）13：30，会期半天。 网络投票时间：2024 年 5 月 22 日，其中通过深圳证券交易所交易系统进行 网络投票的具体时间为：2024 年 5 月 22 日上午 9:15-9:25，9:30-11:30，下午 13:00 —15:00；通过深圳证券交易所互联网投票系统投票的具体时间为：2024 年 5 月 22 日 9:15—15:00 任意时间。 4.会议召集人：公司董事会 5.会议主持人：董事长徐群辉先生 6.本次股东大会的召集、召开与表决程序符合《公司法》、《上市公司股东大 会规则》、《深圳证券交易所股票上市规则》及《公司章程》等法律、法规及规范 性文件的规定。 ...

上海市锦天城律师事务所 关于浙江新农化工股份有限公司 2023 年年度股东大会的 法律意见书 地址：上海市浦东新区银城中路 501 号上海中心大厦 9、11、12 层 电话：021-20511000 传真：021-20511999 邮编：200120 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于浙江新农化工股份有限公司 2023 年年度股东大会的 法律意见书 致：浙江新农化工股份有限公司 上海市锦天城律师事务所（以下简称本所）接受浙江新农化工股份有限公司 （以下简称公司）委托，就公司召开 2023 年年度股东大会（以下简称本次股东 大会）的有关事宜，根据《中华人民共和国公司法》（以下简称《公司法》）、 《上市公司股东大会规则》等法律、法规、规章和其他规范性文件以及《浙江新 农化工股份有限公司章程》（以下简称《公司章程》）的有关规定，出具本法律 意见书。 为出具本法律意见书，本所及本所律师依据《律师事务所从事证券法律业务 管理办法》和《律师事务所证券法律业务执业规则（试行）》等规定，严格履行 了法定职责，遵循了勤勉尽责和诚实信用原则，对本次股东大会所涉及的相关事 项进行了必要的核查和验证，核 ...

证券代码：002942 证券简称：新农股份 浙江新农化工股份有限公司 投资者关系活动记录表 | 编号：2024-001 | | --- | 答:噻唑锌是公司拥有自主知识产权的创制杀菌剂。噻唑锌及其 系列复配制剂产品聚焦细菌性病害市场及细菌与真菌性病害混发市 场，以其独特的安全性、可混性、补锌保健等功效，广泛应用于粮食、 果树、蔬菜等经济作物，得到市场的普遍认可。对于噻唑锌（碧生） 公司制定了长远的发展规划：不急功近利做短期，而是对标跨国企业 做具有品牌影响力的大单品。 公司通过聚焦核心作物，深耕目标市 场，持续了解用户需求并进行技术迭代，以技术营销服务为抓手，不 断提升噻唑锌系列（碧氏系列）制剂产品的应用领域及市场覆盖度。 根据"小步国际化、走向东南亚"业务规划和定位，海外噻唑锌制剂业 务聚焦重点国家、聚焦核心作物，嫁接合作伙伴优质渠道，业务模式 和团队建设持续深化优化，市场规划、产品登记、渠道拓展等各项工 作有序推进。公司将笃定以制剂业务为龙头的差异化竞争策略，以碧 生"创杀细菌剂第一品牌"为引领，实现公司的可持续发展。感谢您对 公司的关注！ 4.对于去年下半年净利润亏损作何解释？ 答:尊敬的投资者，您好！ ...

证券代码：002942 证券简称：新农股份 投资者关系活动记录表 | 编号：2024-001 | | --- | | 投资者关系活动类别 | ☐特定对象调研 ☐分析师会议 | | --- | --- | | | ☐媒体采访 业绩说明会 | | | ☐新闻发布会 ☐路演活动 | | | ☐现场参观 | | | ☐其他（请文字说明其他活动内容） | | 参与单位名称及人员姓名 | 参与公司2023年度暨2024年第一季度网上业绩说明会的全体投资者 | | 时间 | 2024年05月15日 15:00-17:00 | | 地点 | 价值在线（https://www.ir-online.cn/）网络互动 | | 上市公司接待人员姓名 | 董事长兼总经理 徐群辉 | | | 副总经理兼董事会秘书 姚钢 | | | 财务总监 丁珍珍 | | | 独立董事 董黎明 1.公司在净利润为负的情况下，为什么还能拿出钱来分红？是 | | | 否会影响到公司经营所需资金？ | | 投资者关系活动主要内容 | 答:尊敬的投资者，您好！公司自2018年上市以来，坚持每年实 | | 介绍 | 施现金分红，给予投资者稳定、合理的回报。20 ...

证券代码：002942 证券简称：新农股份 公告编号：2024-027 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示： 浙江新农化工股份有限公司 关于举行 2023 年度暨 2024 年第一季度 网上业绩说明会的公告 浙江新农化工股份有限公司（以下简称"公司"）《2023 年年度报告》及其 摘要、《2024 年第一季度报告》已于 2024 年 4 月 25 日在公司指定信息披露媒体 《证券时报》和巨潮资讯网（www.cninfo.com.cn）上披露。为便于广大投资者 更深入、全面地了解公司的经营业绩、发展战略等情况，公司定于 2024 年 5 月 会议召开时间：2024 年 5 月 15 日（星期三）15:00-17:00 会议召开方式：网络互动方式 会议召开地点：价值在线（www.ir-online.cn） 会议问题征集：投资者可于 2024 年 5 月 15 日（周三）前访问网址 https://eseb.cn/1dZwh2CWWv6 或使用微信扫描下方小程序码进行会前提问， 公司将通过本次业绩说明会，在信息披露允许范围内就投资者普遍关注 ...

浙江新农化工股份有限公司 2023 年度审计报告 中国杭州市钱江新城新业路8号UDC时代大厦A座5-8层、12层、23层 Floors 5–8, 12 and 23, Block A, UDC Times Building, No 8 Xinye Road, Qianjiang New City, Hangzhou Tel. 0571-88879999 Fax. 0571-88879000 www.zhcpa.cn 行证明该审计报告是否由具有执业许可的会计师事务 十师行业统一监管平台（http://acc.mof.gov.cn） 您可使用手机"扫一扫"或进入 编码:浙2446F 目 录 | 页 次 | | | --- | --- | | 一、审计报告 | 1-6 | | 二、财务报表 | 7-18 | | (一) 合并资产负债表 | 7-8 | | (二) 合并利润表 | 9 | | (三) 合并现金流量表 | 10 | | (四) 合并所有者权益变动表 | 11-12 | | (五) 母公司资产负债表 | 13-14 | | (六) 母公司利润表 | 15 | | (七) 母公司现金流量表 | 16 | | ...

[Report Summary and Key Financial Indicators](index=6&type=section&id=Item%202.%20Company%20Profile%20and%20Key%20Financial%20Indicators) [Company Profile](index=6&type=section&id=Item%201.%20Company%20Information) Zhejiang Xinnong Chemical Co., Ltd. (stock code: 002942) is a Shenzhen-listed company specializing in the R&D, production, and sales of chemical pesticides and intermediates - The company is a chemical enterprise listed on the Shenzhen Stock Exchange, stock code **002942**, primarily engaged in the R&D, production, and sales of chemical pesticides[15](index=15&type=chunk) [Core Financial Data](index=7&type=section&id=Item%206.%20Key%20Accounting%20Data%20and%20Financial%20Indicators) In 2023, the company's performance significantly declined, with revenue decreasing by 34.22% to 821 million yuan and net profit attributable to shareholders turning from profit to loss at -25 million yuan Key Financial Indicators | Indicator | 2023 | 2022 | YoY Change | | :--- | :--- | :--- | :--- | | **Operating Revenue (yuan)** | 821,032,278.60 | 1,248,167,151.74 | -34.22% | | **Net Profit Attributable to Parent (yuan)** | -25,374,268.50 | 101,397,042.30 | -125.02% | | **Non-recurring Net Profit Attributable to Parent (yuan)** | -43,594,379.46 | 91,855,675.41 | -147.46% | | **Net Cash Flow from Operating Activities (yuan)** | 90,476,478.57 | 138,071,733.77 | -34.47% | | **Basic Earnings Per Share (yuan/share)** | -0.17 | 0.66 | -125.76% | | **Weighted Average Return on Net Assets** | -2.21% | 8.79% | -11.00 percentage points | | **Total Assets (yuan)** | 1,476,010,746.37 | 1,640,799,914.94 | -10.04% | | **Net Assets Attributable to Parent (yuan)** | 1,121,841,233.36 | 1,171,255,911.40 | -4.22% | [Quarterly Financial Performance](index=8&type=section&id=Item%208.%20Key%20Quarterly%20Financial%20Indicators) The company's 2023 performance showed a quarterly decline, turning to loss in Q3 and significantly widening in Q4, while operating cash flow improved in the latter half Quarterly Financial Indicators | Financial Indicator (yuan) | Q1 | Q2 | Q3 | Q4 | | :--- | :--- | :--- | :--- | :--- | | **Operating Revenue** | 275,296,537.41 | 209,537,984.85 | 176,637,399.08 | 159,560,357.26 | | **Net Profit Attributable to Parent** | 10,792,398.23 | 14,847,010.13 | -3,529,677.55 | -47,483,999.31 | | **Non-recurring Net Profit Attributable to Parent** | 3,253,361.65 | 13,396,428.82 | -7,298,608.89 | -52,945,561.04 | | **Net Cash Flow from Operating Activities** | -54,289,133.02 | 39,615,374.33 | 25,822,523.87 | 79,327,713.39 | [Dividend Distribution Plan](index=2&type=section&id=Important%20Notice%2C%20Table%20of%20Contents%2C%20and%20Definitions) The board proposed a 2023 profit distribution plan of a cash dividend of 2 yuan (tax inclusive) per 10 shares, based on total shares minus repurchased shares - The company's 2023 profit distribution plan proposes a cash dividend of **2 yuan (tax inclusive)** per **10 shares**, based on **153,209,930 shares** after deducting repurchased shares[4](index=4&type=chunk) [Management Discussion and Analysis](index=10&type=section&id=Item%203.%20Management%20Discussion%20and%20Analysis) [Industry Overview and Company Positioning](index=10&type=section&id=Item%201.%20Industry%20Conditions%20During%20the%20Reporting%20Period) In 2023, the domestic pesticide market faced intensified competition due to oversupply, driving a shift towards green pesticides and favoring integrated, R&D-capable companies, with the company's core product, Thiazinc, maintaining strong market competitiveness - In 2023, domestic pesticide market competition intensified, leading to oversupply and an expected increase in industry concentration[36](index=36&type=chunk) - Policies encourage the development of efficient, safe, and environmentally friendly pesticide varieties and formulations, with highly toxic and high-residue pesticides gradually exiting the market[36](index=36&type=chunk) - The company's core product, **Thiazinc**, is an independently developed fungicide with high market recognition and strong competitiveness in bacterial disease control[38](index=38&type=chunk) [Main Business and Products](index=11&type=section&id=Item%202.%20Main%20Businesses%20Engaged%20in%20During%20the%20Reporting%20Period) The company's main business covers the entire pesticide industry chain, from intermediates to formulations, with core products including Thiazinc fungicides and Chlorpyrifos/Triazophos insecticides; however, capacity utilization was generally low in 2023, and overseas sales accounted for 20.97% of total revenue Production Capacity and Utilization | Main Product | Designed Capacity | Capacity Utilization Rate | Capacity Under Construction | | :--- | :--- | :--- | :--- | | **Formulations** | 9,000 tons/year | 72.27% | 20,000 tons/year | | **Technical Concentrates** | 11,000 tons/year | 58.59% | 700 tons/year | | **Intermediates** | 28,800 tons/year | 31.51% | 6,500 tons/year | - The company's proprietary **Thiazinc** series formulations are estimated to hold an **11-13%** market share in bacterial disease control[54](index=54&type=chunk) - Overseas sales revenue in 2023 was **172 million yuan**, accounting for **20.97%** of total revenue, indicating a relatively small scale[59](index=59&type=chunk) [Core Competencies](index=18&type=section&id=Item%203.%20Analysis%20of%20Core%20Competencies) The company's core competencies include strong technological innovation, an integrated industrial chain, differentiated product advantages, a robust brand and market presence, and excellent safety and environmental management - The company possesses a comprehensive R&D system, recognized as a National High-Tech Enterprise and National Intellectual Property Advantage Enterprise, with **150 accumulated patents** (including **58 invention patents**) as of the reporting period end[60](index=60&type=chunk)[61](index=61&type=chunk) - The company adopts an integrated 'intermediate-technical concentrate-formulation' industrial chain model, effectively reducing transaction costs and ensuring product quality and stable supply[62](index=62&type=chunk) - The core product, **Thiazinc**, is a proprietary patented product with uniqueness and high recognition in bacterial disease control, having received multiple national and provincial science and technology awards[65](index=65&type=chunk) - The company has established a sales network covering over **20 provinces** nationwide and maintains long-term strategic partnerships with international agrochemical companies like BASF, Corteva, and Bayer[69](index=69&type=chunk) [Operating Results Analysis](index=20&type=section&id=Item%204.%20Analysis%20of%20Main%20Business) In 2023, the company's operating performance significantly declined due to industry downturn and price drops, but its formulation business showed resilience, increasing its revenue contribution despite overall revenue decrease [Overall Operating Review](index=20&type=section&id=1.%20Overview) The company actively responded to the agrochemical industry downturn by implementing differentiated strategies for formulations and industrial products, increasing R&D investment to 7.10% of revenue, and achieving zero safety and environmental incidents - Facing industry downturn, the company implemented a 'win by professionalism, system for future' strategy, prioritizing a differentiated approach led by the formulation business and a 'cost-performance' strategy for industrial products[74](index=74&type=chunk)[76](index=76&type=chunk) - R&D expenses in 2023 totaled **58.33 million yuan**, accounting for **7.10%** of operating revenue[78](index=78&type=chunk) [Revenue and Cost Analysis](index=21&type=section&id=2.%20Revenue%20and%20Costs) In 2023, total revenue decreased by 34.22% to 821 million yuan, with intermediates and technical concentrates experiencing significant declines in both revenue and gross margin due to market downturn and price drops Revenue and Gross Margin by Product | By Product | Operating Revenue (yuan) | YoY Revenue Change | Gross Margin | YoY Gross Margin Change | | :--- | :--- | :--- | :--- | :--- | | **Formulations** | 356,752,379.12 | -7.80% | 47.12% | -3.40 percentage points | | **Technical Concentrates** | 185,215,529.83 | -29.97% | -11.94% | -17.31 percentage points | | **Intermediates** | 256,564,409.37 | -54.28% | 9.11% | -7.83 percentage points | - Prices for technical concentrates and intermediate products showed a downward trend during the reporting period, primarily due to industry downturn and oversupply[85](index=85&type=chunk) [Expense Analysis](index=24&type=section&id=3.%20Expenses) Sales and administrative expenses remained stable in 2023, while financial expenses decreased due to reduced foreign exchange gains, and R&D expenses saw a 16.96% year-on-year decrease Key Expense Items | Expense Item | 2023 (yuan) | 2022 (yuan) | YoY Change | Main Change Explanation | | :--- | :--- | :--- | :--- | :--- | | **Selling Expenses** | 56,570,979.94 | 57,520,825.67 | -1.65% | No significant change | | **Administrative Expenses** | 96,546,522.89 | 91,129,118.33 | 5.94% | No significant change | | **Financial Expenses** | -4,037,649.98 | -12,766,428.95 | Not applicable | Primarily due to impact of USD exchange rate fluctuations on exchange gains | | **R&D Expenses** | 58,328,564.13 | 70,237,536.36 | -16.96% | No significant change | [R&D Investment](index=24&type=section&id=4.%20R%26D%20Investment) In 2023, total R&D investment was 60.28 million yuan, representing 7.34% of operating revenue, an increase from the previous year, with R&D efforts focused on process optimization, cost reduction, and new product development R&D Investment Overview | R&D Investment | 2023 | 2022 | Change Percentage | | :--- | :--- | :--- | :--- | | **R&D Investment Amount (yuan)** | 60,283,381.65 | 70,237,536.36 | -14.17% | | **R&D Investment as % of Revenue** | 7.34% | 5.63% | 1.71 percentage points | | **Number of R&D Personnel (persons)** | 174 | 178 | -2.25% | | **R&D Personnel as % of Total Staff** | 14.68% | 12.35% | 2.33 percentage points | [Cash Flow Analysis](index=25&type=section&id=5.%20Cash%20Flow) In 2023, net cash flow from operating activities decreased by 34.47% due to lower sales, while net cash outflow from financing activities significantly reduced due to decreased dividend distribution - Net cash flow from operating activities was **90,476,478.57 yuan**, a **34.47%** year-on-year decrease, primarily due to reduced cash received from sales of goods and services[96](index=96&type=chunk)[97](index=97&type=chunk) - Net cash outflow from financing activities decreased year-on-year, mainly due to a reduction in dividend distribution for the current year[97](index=97&type=chunk)[98](index=98&type=chunk) [Assets and Liabilities Status](index=26&type=section&id=Item%206.%20Analysis%20of%20Assets%20and%20Liabilities%20Status) As of 2023 year-end, total assets decreased by 10.04% to 1.476 billion yuan, while total liabilities decreased by 24.57% to 354 million yuan, improving the asset-liability ratio to 24.00% and reflecting a more stable financial structure - As of 2023 year-end, the company's total assets were **1.476 billion yuan**, a **10.04%** year-on-year decrease; total liabilities were **354 million yuan**, a **24.57%** year-on-year decrease[99](index=99&type=chunk)[314](index=314&type=chunk) - The asset-liability ratio at year-end was **24.00%**, a decrease from **28.62%** at the beginning of the period, indicating an improved financial structure[759](index=759&type=chunk) - The book value of restricted assets at year-end was **16.90 million yuan**, primarily consisting of bank acceptance bill and forward foreign exchange settlement and sales deposits, a significant decrease from **52.74 million yuan** at the beginning of the period[102](index=102&type=chunk)[103](index=103&type=chunk) [Future Outlook and Risks](index=38&type=section&id=Item%2011.%20Outlook%20on%20the%20Company%27s%20Future%20Development) The company anticipates accelerated green transformation and consolidation in the pesticide industry, focusing on a differentiated strategy led by formulations and Thiazinc, while addressing market competition, raw material price volatility, and safety/environmental risks [Development Strategy and 2024 Operating Plan](index=39&type=section&id=2.%20Company%20Development%20Strategy) The company's development strategy focuses on differentiation, with formulations as the lead, combining innovation and imitation, and synergistic development of chemical and biological pesticides, supported by a 2024 plan to optimize marketing, enhance R&D, strengthen QEHS, and build professional teams - Company strategy: Focus on differentiation, with formulations as the lead, combining innovation and imitation, and an integrated model of synergistic development of chemical and biological pesticides[142](index=142&type=chunk) - 2024 plan: Continue to focus on **6+1 core crops**, improve channel management, expand strategic products, and accelerate new product development in chemical pesticides and biological formulations[143](index=143&type=chunk)[144](index=144&type=chunk) [Key Risks and Countermeasures](index=40&type=section&id=4.%20Potential%20Risk%20Factors%20and%20Countermeasures) The company faces key risks including market competition, raw material price volatility, safety and environmental pressures, and operational management challenges from expansion, which it addresses through continuous technical upgrades, procurement control, increased safety/environmental investment, and improved management structures - Key risks include market competition, raw material price fluctuations, production safety, environmental protection, and operational management risks[147](index=147&type=chunk)[148](index=148&type=chunk)[149](index=149&type=chunk)[150](index=150&type=chunk)[151](index=151&type=chunk) [Corporate Governance and Internal Control](index=42&type=section&id=Item%204.%20Corporate%20Governance) [Corporate Governance Structure](index=42&type=section&id=Item%201.%20Basic%20Status%20of%20Corporate%20Governance) The company operates in strict compliance with laws and regulations, maintaining a sound corporate governance structure with independent assets, personnel, finance, organization, and operations, ensuring effective checks and balances - The company's corporate governance structure is sound, compliant with laws and regulations, and maintains independence from the controlling shareholder in terms of assets, personnel, finance, organization, and operations[155](index=155&type=chunk)[157](index=157&type=chunk) [Directors, Supervisors, and Senior Management](index=44&type=section&id=Item%205.%20Information%20on%20Directors%2C%20Supervisors%2C%20and%20Senior%20Management) During the reporting period, the company experienced a change in senior management with the resignation of the former Vice General Manager and CFO, Mr. He Hongyun, and the appointment of Ms. Ding Zhenzhen as the new CFO - During the reporting period, Vice General Manager and CFO He Hongyun resigned, and the company appointed **Ding Zhenzhen** as the new CFO[164](index=164&type=chunk) [Internal Control](index=54&type=section&id=Item%2012.%20Construction%20and%20Implementation%20of%20Internal%20Control%20System%20During%20the%20Reporting%20Period) The company continuously improved its internal control system, and as of December 31, 2023, maintained effective internal controls over financial reporting in all material aspects, with no significant deficiencies identified by the board or auditors - The company's board of directors believes that the internal control design is sound and effectively implemented, with no significant deficiencies[197](index=197&type=chunk) - The accounting firm issued a standard unqualified audit opinion on the effectiveness of the company's internal controls over financial reporting as of December 31, 2023[202](index=202&type=chunk) [Environmental, Social Responsibility, and Other Significant Matters](index=56&type=section&id=Item%205.%20Environmental%20and%20Social%20Responsibility) [Environmental Protection](index=56&type=section&id=Item%201.%20Major%20Environmental%20Issues) The company and its subsidiaries are key pollutant discharge units, adhering to environmental regulations; however, subsidiary Jiangsu Xinnong received a 190,000 yuan fine for wastewater discharge exceedance, which has since been rectified - The company and its subsidiaries, Xinnong Co., Xinnong Technology, and Jiangsu Xinnong, are all designated as key pollutant discharge units by environmental protection authorities[205](index=205&type=chunk) - During the reporting period, subsidiary Jiangsu Xinnong was fined **190,000 yuan** for exceeding wastewater total nitrogen discharge limits and has completed rectification[224](index=224&type=chunk) [Social Responsibility](index=61&type=section&id=Item%202.%20Social%20Responsibility%20Status) The company actively fulfills its social responsibilities, including legal compliance, protecting stakeholder rights, ensuring employee welfare, maintaining supplier/customer relations, and engaging in public welfare, consistently providing cash dividends since listing and achieving zero safety accidents in 2023 - The company prioritizes investor returns, having distributed cash dividends annually since its listing, with cumulative distributed profits totaling **289.2 million yuan**[227](index=227&type=chunk) - All major production bases have established comprehensive safety management systems, with **no safety production accidents** occurring throughout 2023[233](index=233&type=chunk)[235](index=235&type=chunk)[238](index=238&type=chunk) [Other Significant Matters](index=64&type=section&id=Item%206.%20Significant%20Matters) During the reporting period, the company fulfilled commitments, had no major litigation or related-party transactions, changed accounting policies due to new regulations, extended the '1,000 tons/year Pyraclostrobin' project, and both the company and Taizhou Xinnong were re-certified as high-tech enterprises - The company's fundraising project, 'Annual Production of **1,000 tons of Pyraclostrobin** and By-product **430 tons of Sodium Chloride Project**,' had its expected usable date extended due to process optimization and debugging[274](index=274&type=chunk) - Both the company and its wholly-owned subsidiary, Taizhou Xinnong Technology Co., Ltd., were re-certified as High-Tech Enterprises, valid for three years, entitling them to a preferential corporate income tax rate of **15%**[274](index=274&type=chunk)[275](index=275&type=chunk) [Share Changes and Shareholder Information](index=74&type=section&id=Item%207.%20Share%20Changes%20and%20Shareholder%20Information) [Share Changes](index=74&type=section&id=Item%201.%20Share%20Change%20Status) During the reporting period, the company's total share capital remained at 156 million shares, with a structural change in restricted and unrestricted shares due to the former supervisor's departure and subsequent release of his shares from restrictions - Total share capital remained unchanged at **156,000,000 shares** during the reporting period, with a structural change between restricted and unrestricted shares due to a senior executive's departure[278](index=278&type=chunk) [Major Shareholder Information](index=75&type=section&id=Item%203.%20Shareholder%20and%20Actual%20Controller%20Information) As of the reporting period end, the company had 9,383 shareholders, with Zhejiang Xinhui Investment Co., Ltd. as the controlling shareholder (54.50%), and the Xu Qunhui, Xu Yuexing, Pan Yuyan family as the actual controllers, collectively holding 64.31% of shares Top Shareholders | Shareholder Name | Shareholder Nature | Shareholding Percentage | Number of Shares Held at Period End | | :--- | :--- | :--- | :--- | | **Zhejiang Xinhui Investment Co., Ltd.** | Domestic Non-State-owned Legal Person | 54.50% | 85,020,000 | | **Xu Qunhui** | Domestic Natural Person | 5.06% | 7,897,500 | | **Pan Yuyan** | Domestic Natural Person | 3.50% | 5,460,000 | | **Hu Hong** | Domestic Natural Person | 2.31% | 3,599,700 | | **Guotai Juxin Value Advantage Mixed** | Fund | 1.95% | 3,045,900 | - The company's actual controllers are **Xu Qunhui**, **Xu Yuexing**, and **Pan Yuyan**, with Xu Yuexing and Pan Yuyan being a married couple and Xu Qunhui's parents[284](index=284&type=chunk)[288](index=288&type=chunk) [Financial Report and Audit Opinion](index=81&type=section&id=Item%2010.%20Financial%20Report) [Audit Report](index=81&type=section&id=Item%201.%20Audit%20Report) Zhonghui Certified Public Accountants (Special General Partnership) issued a standard unqualified audit opinion on the company's 2023 financial statements, confirming fair presentation in all material aspects, with revenue recognition identified as a key audit matter - The auditing firm issued a standard unqualified audit opinion[296](index=296&type=chunk) - A key audit matter was 'revenue recognition from main operations' due to its material amount and inherent risk of management override[297](index=297&type=chunk)[298](index=298&type=chunk) [Significant Accounting Policy Changes](index=69&type=section&id=Item%206.%20Explanation%20of%20Changes%20in%20Accounting%20Policies%2C%20Accounting%20Estimates%2C%20or%20Significant%20Accounting%20Error%20Corrections%20Compared%20to%20Prior%20Year%27s%20Financial%20Report) During the reporting period, the company changed its accounting policies in accordance with 'Interpretation No. 16 of Accounting Standards for Business Enterprises' issued by the Ministry of Finance, primarily concerning deferred income tax related to single transactions, with retrospective adjustments made to relevant financial statement items - The company adopted 'Interpretation No. 16 of Accounting Standards for Business Enterprises' issued by the Ministry of Finance starting January 1, 2023, and retrospectively adjusted deferred income tax arising from related transactions[253](index=253&type=chunk)[507](index=507&type=chunk) [Notes to Major Items in Consolidated Financial Statements](index=130&type=section&id=Item%207.%20Notes%20to%20Consolidated%20Financial%20Statement%20Items) Financial statement notes indicate decreases in accounts receivable and inventory, with bad debt provision reversals and inventory/fixed asset impairment provisions reflecting asset quality management pressures, while non-recurring gains partially offset operating losses - Accounts receivable balance at period-end was **91.19 million yuan**, a significant decrease from **147 million yuan** at the beginning of the period; **2.65 million yuan** in bad debt provisions were reversed this period[521](index=521&type=chunk)[527](index=527&type=chunk) - Inventory book value at period-end was **102 million yuan**, a decrease from **155 million yuan** at the beginning of the period; **11.57 million yuan** in inventory impairment provisions were recognized this period, mainly for finished goods[557](index=557&type=chunk)[559](index=559&type=chunk) - Fixed asset impairment provisions of **6.74 million yuan** were recognized this period, primarily for machinery and equipment no longer expected to be in use[569](index=569&type=chunk)[573](index=573&type=chunk) - Total non-recurring gains and losses for the current period amounted to **18.22 million yuan**, primarily comprising **9.36 million yuan** in government grants and **12.40 million yuan** in financial asset investment-related gains/losses[818](index=818&type=chunk)

2023 年度非经营性资金占用及其他关联资金往来情况汇总表 单位：万元 非经营性资金占用 资金占用方名称 占用方与上市 公司的关联关 系 上市公司核算 的会计科目 2023 年年期 初占用资金 余额 2023 年年度占用 累计发生金额 （不含利息） 2023 年年度占 用资金的利息 （如有） 2023 年年度偿 还累计发生金 额 2023 年年期末 占用资金余额 占用形成原因 占用性质 控股股东、实际控制 人及其附属企业 非经营性占用 小计 - - - - 前控股股东、实际控 制人及其附属企业 非经营性占用 小计 - - - - 其他关联方及其附 属企业 非经营性占用 小计 - - - - 总计 - - - - | | | 往来方与上市 | 上市公司核算 | 2023 年年期 | 2023 年年度往来 | | 2023 年年度往 | 2023 | 年年度偿 | 2023 年年期末 | | 往来性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 其他关联资金往来 | 资金往来方名称 | 公司 ...

根据中国证券监督管理委员会《上市公司独立董事管理办法》、《深圳证券交 易所股票上市规则》、《深圳证券交易所上市公司自律监管指引第 1 号——主板上 市公司规范运作》等要求，浙江新农化工股份有限公司（以下简称"公司"）董 事会，就公司在任独立董事刘亚萍、董黎明、徐关寿的独立性情况进行评估并出 具如下专项意见： 经核查独立董事刘亚萍、董黎明、徐关寿的任职经历以及签署的相关自查文 件，上述人员未在公司担任除独立董事、董事会专门委员会委员以外的任何职务， 也未在公司主要股东公司担任任何职务，与公司以及主要股东之间不存在利害关 系或其他可能妨碍其进行独立客观判断的关系。因此，公司独立董事符合《上市 公司独立董事管理办法》、《深圳证券交易所上市公司自律监管指引第 1 号——主 板上市公司规范运作》中对独立董事独立性的相关要求。 浙江新农化工股份有限公司 董事会 2024 年 4 月 24 日 浙江新农化工股份有限公司 关于独立董事独立性情况的专项意见 ...

浙江新农化工股份有限公司 《公司章程》修订对照表 | 序 号 | 修订前 | 修订后 | | --- | --- | --- | | 6 | 第八十八条 股东大会对提案进行表决 监票。审议事项与股东有利害关系的， | 第八十八条 股东大会对提案进行表决前， 审议事项与股东有关联关系的，相关股东 | | | 前，应当推举 2 名股东代表参加计票和 | | | | | 应当推举 2 名股东代表参加计票和监票。 | | | 相关股东及代理人不得参加计票、监 | | | | 票。 | 及代理人不得参加计票、监票。 | | 7 | | 各章节序号顺延 | （经公司第六届董事会第九次会议审议通过，尚需提交 2023 年年度股东大会审议） | 序 | 修订前 | 修订后 | | --- | --- | --- | | 号 | | | | | | 东大会的，须书面通知董事会，同时向公 | | | 第五十一条 监事会或股东决定自行召 集股东大会的，须书面通知董事会，同 | 第五十一条 监事会或股东决定自行召集股 | | | 时向公司所在地中国证监会派出机构和 | 司所在地中国证监会派出机构和证券交易 | | | 证券交易所备案 ...